Aehr Test (AEHR) Q3 2026 Earnings Call Transcript

Q3 revenue of $10.3M fell 44% year-over-year, driving a non-GAAP net loss of $1.5M (-$0.05/share), but bookings surged to $37.2M and effective backlog reached a record $50.9M. Company fully drew $40M from its ATM program (raised >$40M gross proceeds) and ended the quarter with $37.1M cash, and expects FY2026 revenue on the high side of $45–$50M and a return to non-GAAP profitability in Q4. Management reported major $14M AI wafer-level burn-in follow-on, new silicon photonics and package-level Sonoma wins, and added contract-manufacturing capacity for >20 Sonoma systems/month, supporting a bullish multi-market pipeline despite near-term revenue weakness.

Analysis

Aehr’s recent commentary exposes a classic enterprise-software-to-hardware adoption inflection: engineering wins are cascading into production contracts, which should drive durable consumables revenue that scales faster than systems shipments. The critical second-order lever is consumables cadence — once multiple hyperscalers and photonics fabs standardize on WaferPaks and burn-in boards, revenue per installed system shifts from lumpy capital sales to predictable, high-margin recurring spend, materially expanding lifetime value per customer over 12–36 months.

Manufacturing scale is the operational fulcrum. Outsourcing Sonoma builds to contract manufacturers reduces Aehr’s incremental capital intensity and shortens time-to-volume, but it also pushes execution risk into partner on-time delivery, quality control, and kit supply (WaferPaks). That creates a near-term mismatch risk: backlog visibility improves, but recognition and margin realization will hinge on CM ramp quality and WaferPak supply chain throughput over the next 2–6 quarters.

Investor risk is dominated by two offsetting forces: (1) equity dilution/ATM exhaustion that raises headline supply pressure and amplifies downside on any execution miss, and (2) an addressable market expansion tied to wafer-level adoption across AI, photonics, memory and wide-bandgap power — a multi-year structural tailwind. The calendar/fiscal-year shift and the stub month create an asymmetric near-term catalyst schedule where a single quarterly conversion miss could compress multiples despite durable long-term economics.

Key Decisions for Investors

• Small, conviction-weighted long AEHR (1–2% portfolio) with a 12–18 month horizon: initiate on a technical or news-driven pullback (~20% below last trade) or immediately if comfortable with volatility. Target 2.5–3.5x upside if backlog converts and consumables cadence normalizes; hard stop 30% to limit ATM/dilution-driven downside.
• Leveraged options: buy AEHR Jan 2027 call spread (long Jan 2027 $40 call, short Jan 2027 $70 call) sized to risk no more than 0.5% portfolio. Rationale: asymmetric payoff to capture fiscal '27 ramp while capping premium loss if wafer-level adoption lags; roll up on confirmed consumables monthly revenue growth or visible CM throughput improvement.
• Tactical hedge / event short trigger: establish a small (0.5% portfolio) short or buy put protection if Q4 revenue falls >10% short of management’s high-side guidance or if company announces >$10M incremental equity beyond ATM. Risk/reward favors protection — a single miss could reprice multiple compression by 30–50%.